MESO-02

• Research type

  Research Study

• Full title

  A phase I/II study of first line Ganetespib with pemetrexed/cisplatin, in patients with malignant pleural mesothelioma

• IRAS ID

  106293

• Contact name

  Dean Fennell

• Sponsor organisation

  University College London

• Eudract number

  2012-001598-10

• Clinicaltrials.gov Identifier

  NCT01590160

• Research summary

  Mesothelioma is a relatively rare cancer which is becoming more common. It can affect one of two areas; the pleura (the lining of the lung) or the peritoneum (the lining of the abdomen). Cancer affecting the pleura is the more common of these and is called Pleural Mesothelioma. This is most commonly caused by exposure to asbestos. Unfortunately mesothelioma is usually diagnosed at an advanced stage and so treatment is based around controlling the disease and managing the symptoms, rather than curing the disease. The standard treatment for Advanced Malignant Pleural Mesothelioma is a combination of two anti-cancer drugs; Pemetrexed and Cisplatin. The trial will look into whether there are benefits of adding a third drug called Ganetespib to the treatment.

• REC name

  East Midlands - Derby Research Ethics Committee

• REC reference

  12/EM/0448

• Date of REC Opinion

  21 Dec 2012

• REC opinion

  Further Information Favourable Opinion